New York, Jan 26, 2026, 21:03 EST — Market closed.
- Boston Scientific shares rose Monday, building on gains from the previous session.
- Investors continue to zero in on the Penumbra acquisition amid recent safety concerns surrounding its devices.
- Next up: Boston Scientific’s quarterly results and conference call on Feb. 4.
Shares of Boston Scientific Corp climbed 1.12% to $93.55 on Monday, while the S&P 500 edged up 0.50% and the Dow Jones Industrial Average gained 0.64%. The stock underperformed Abbott Laboratories and Stryker but outpaced Medtronic. Trading volume stayed above its 50-day average. Despite Monday’s gain, shares remain roughly 14.6% below their 52-week peak from September.
After the closing bell, all eyes turn to whether BSX can stay firm. Investors are weighing a major deal reshaping its portfolio against a steady stream of device news that could quickly add up to expenses.
Boston Scientific revealed earlier this month it will acquire Penumbra in a cash-and-stock deal worth about $14.5 billion. Around 73% of the price will be paid in cash, with the remainder in stock. The $11 billion cash portion will come from existing funds and new debt. CEO Mike Mahoney described the move as a chance to break into fast-growing vascular segments. Penumbra CEO Adam Elsesser highlighted their focus on “deep innovation for complex diseases.” Boston Scientific expects the deal to reduce adjusted earnings per share by $0.06 to $0.08 in the first full year post-close. The acquisition is slated to wrap up in 2026, pending Penumbra shareholder approval and other conditions. Boston Scientific
Neuromodulation, a smaller segment but one eyed for steady growth, drew fresh buzz at the conference. Boston Scientific announced 17 abstracts accepted for the North American Neuromodulation Society meeting in Las Vegas. It also highlighted upcoming long-term data on spinal cord stimulation for chronic pain. “The data … underscore our category leadership in the pain space,” said Jim Cassidy, president of Neuromodulation at Boston Scientific. Boston Scientific
Regulators have zeroed in on one of the company’s GI products. The U.S. Food and Drug Administration issued an “early alert” concerning certain AXIOS stent and electrocautery-enhanced delivery systems, highlighting deployment and expansion problems during procedures. Boston Scientific reportedly told customers to halt use and distribution of affected lots. As of Dec. 23, the FDA recorded 167 serious injuries and three deaths linked to the issue, which arises during delivery—not with successfully implanted stents. U.S. Food and Drug Administration
For traders, the takeaway is clear: Penumbra advances Boston Scientific’s foothold in mechanical thrombectomy — a catheter-based method for removing blood clots — yet it also raises immediate concerns about financing and integration. Debt expenses are a factor, as is the pace at which the merged sales teams can push the broader product range without losing focus.
Momentum in procedures is another key factor. Boston Scientific’s revenue depends on doctors performing cases. Any sign of volume slowing down—due to hospital staffing issues, reimbursement hurdles, or product disruptions—usually hits sentiment fast.
There is a downside risk. Should the Penumbra deal face delays or prove pricier than anticipated, or if the AXIOS matter escalates into wider repercussions, the stock’s recent rally might stall—right as the market shifts focus to 2026 projections.
Boston Scientific is set to report its fourth-quarter and full-year 2025 results on Feb. 4, ahead of an 8:00 a.m. ET conference call with CEO Mahoney and CFO Jon Monson.
